Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Robert W. Baird

Robert W. Baird began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report report published on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $31.00 price target on the stock.

A number of other equities analysts have also issued reports on DNLI. HC Wainwright reduced their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. William Blair assumed coverage on Denali Therapeutics in a research report on Friday, January 3rd. They issued an “outperform” rating on the stock. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $21.18 on Tuesday. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market cap of $3.05 billion, a PE ratio of -7.67 and a beta of 1.39. The business has a 50-day simple moving average of $24.34 and a two-hundred day simple moving average of $24.88.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the firm earned ($0.72) EPS. On average, sell-side analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Alexander O. Schuth sold 15,558 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,658 shares of company stock valued at $1,667,943. 7.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DNLI. CWM LLC raised its stake in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 654 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Denali Therapeutics during the third quarter worth $73,000. Assetmark Inc. raised its position in shares of Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after buying an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Denali Therapeutics during the second quarter worth about $194,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.